UBS Maintains Neutral on Oscar Health, Raises Price Target to $36

Benzinga Newsdesk www.benzinga.com Neutral 59.6%

Neg 0% Neu 59.6% Pos 0%

UBS analyst Jonathan Yong maintains Oscar Health (NYSE:OSCR) with a Neutral and raises the price target from $26 to $36.